IHAM
COGT icon

Integral Health Asset Management’s Cogent Biosciences COGT Stock Holding History

Integral Health Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.74M Sell
200,000
-150,000
-43% -$5.25M 0.31% 67
2026
Q1 		$13.5M Buy
+350,000
New +$12.9M 0.64% 40

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Integral Health Asset Management's COGT Position: Q2 2026 in Review

Integral Health Asset Management reduced its Cogent Biosciences (COGT) stake by 43% in Q2 2026, selling an estimated $5.25M and leaving 200,000 shares worth $7.74M. The position accounts for 0.31% of the portfolio, ranked #67.

Integral Health Asset Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.5M in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Integral Health Asset Management held 200,000 shares of Cogent Biosciences worth $7.74M as of Q2 2026.
  • Integral Health Asset Management sold 150,000 Cogent Biosciences shares in Q2 2026, an estimated $5.25M.
  • Cogent Biosciences made up 0.31% of Integral Health Asset Management's portfolio in Q2 2026, its #67 holding.
  • Integral Health Asset Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Integral Health Asset Management's Cogent Biosciences position peaked at $13.5M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.